In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
|Videos|July 19, 2017
How Can Pharmacists Promote the Value of the Profession?
Lucinda Maine, Phd, RPh, Executive Vice President and CEO of the American Association of Colleges of Pharmacy (AACP), discusses how pharmacists can promote the value of the profession to their patients and the public.
Advertisement
Lucinda Maine, Phd, RPh, Executive Vice President and CEO of the American Association of Colleges of Pharmacy (AACP), discusses how pharmacists can promote the value of the profession to their patients and the public.
Advertisement
Related to this article
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Reframing Statins and Brain Health Around Stroke Prevention
2
Semaglutide Normalized Liver Fat in Most Adults With Obesity
3
Phase 3 Trial Finds Adding Monoclonal Antibody to mRNA Vaccine Improves COVID-19 Immunization Tolerability
4
mRNA Reenters the Mainstream
5